Reclassification of medicines: BECONASE HAYFEVER RELIEF for ADULTS

Home > Notice-board > Reclassification > Beconase Hayfever Relief for Adults

Beconase Hayfever Relief for Adults

GlaxoSmithKline Consumer Healthcare has asked the Medicines and Healthcare products Regulatory Agency to reclassify Beconase Hayfever (beclomethasone dipropionate 50 mg per spray) as a general sale list medicine. The GSL product will be renamed Beconase Hayfever Relief for Adults. The product will be licensed for the treatment of seasonal allergic rhinitis (hayfever) in adults aged over 18 years.

Consultation period: 9 September 2002 to 21 October 2002.

ARM 5: request to reclassify Beconase Hayfever from P to GSL
(Microsoft Word document)

Reclassification
P to GSL

Status
Completed